PIK3CA mutation in non-metastatic triple-negative breast cancer as a potential biomarker of early relapse: A case report

doi:10.5306/wjco.v12.i8.702

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 12, Issue 8

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (4153)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-11) series.

Item

Count

PDF

351

WORD

HTML

2463

Figures (1-11)

231

Sum=3134

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

327

Download

692

Sum=1019

Aug 24, 2021 (publication date) through Nov 28, 2024

Times Cited of This Article

Times Cited (2)

Journal Information of This Article

Publication Name

World Journal of Clinical Oncology

ISSN

2218-4333

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Case Report

World J Clin Oncol. Aug 24, 2021; 12(8): 702-711
Published online Aug 24, 2021. doi: 10.5306/wjco.v12.i8.702

Full Size Figure Download Figure

Figure 8 List of genes determining the presence of anergic CD8 cells (“exhausted”): “high” result, from the nCounter^®PanCancer Immune Profiling Panel platform.

Citation: Valencia GA, Rioja P, Morante Z, Araujo JM, Vallejos HD, Guerra H, Gomez HL. PIK3CA mutation in non-metastatic triple-negative breast cancer as a potential biomarker of early relapse: A case report. World J Clin Oncol 2021; 12(8): 702-711
URL: https://www.wjgnet.com/2218-4333/full/v12/i8/702.htm
DOI: https://dx.doi.org/10.5306/wjco.v12.i8.702